Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomised, Open-Labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

A Prospective Randomised, Open-Labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Immunosuppressants
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Acronyms SiLVER

    • Most Recent Events

    • 14 Nov 2023 Results (n=508) assessing Validation of the R3-Afp Model for Risk Prediction of Hcc Recurrence after Liver Transplantation presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Jun 2023 Results (n=508) assessing to validate the prognostic and predictive discrimination power of R3-AFP scoring presented at the European Association for the Study of the Liver Congress 2023
    • 01 Nov 2020 Primary endpoint has not been met. (disease-free survival wih Sirolimus)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top